Cerecor Announces Research Grant from the Department of Defense to Study CERC-501 in Animal Models for Co-Morbid Post-Traumatic Stress Disorder and Alcohol Use Disorder (Cerecor Inc)

(Source: Cerecor Inc) BALTIMORE--(BUSINESS WIRE)--Jul. 25, 2016-- Cerecor Inc. (NASDAQ: CERC), a clinical-stage biopharmaceutical company developing treatments to make a difference in the lives of patients with neurological and psychiatric disorders, today announced that the Pharmacotherapies for Alcohol and Substance Use Disorders (PASA) Consortium has provided a grant to Dr. Colin Haile (Principal Investigator, University of Houston), Dr. Therese Kosten (Co-Investigator, University of Houston) and Dr. Ronald Marcus (Co-Investigator, Cerecor) to assess the efficacy of CERC-501, a selective kappa opioid receptor (KOR) antagonist, separately and in combination with one of two...